Anthrogenesis Corporation

Celgene Corporation

Celularity Inc.

Antrhogenesis Corporation

General Electric Company

Clarity Acquisition Ii LLC

Stewart Abbot

Vanessa R Voskinarian-Berse

Tianjian Li

Lin Kang

Robert J Hariri

Jens Rittscher

Eric Law

James W Edinger

Thomas Baby Sebastian

Xiaokui Zhang

Bitao Liang

Jia-Lun Wang

Kristen S Labazzo

Aleksandar Francki

Vladimir Jankovic

Jennifer Paredes

Wei Liu

Aleksandr Kaplunovsky

Kathy Karasiewicz-Mendez

Aleksander Francki

Vanessa Voskinarian-Berse

Katarzyna Karasiewicz-Mendez

Vanessa Voskinarian-berse

Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.

Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis

Provided herein are placental stem cells that exhibit increased survival ('enhanced placental stem cells'), compositions comprising such placental stem cells, and methods of using such placental stem cells and compositions.

Enhanced placental stem cells and uses thereof

Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.

Chimeric antigen receptors

Modified T lymphocytes comprising a BAFF antibody-inducible caspase and methods of apoptosis

Modified T lymphocytes comprising an inducible caspase and methods of apoptosis

Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perforate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrate erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.

Method of producing erythrocytes without feeder cells

Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.

Natural killer cells from placenta

Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.

Angiogenesis using placental stem cells

Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.

Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals.

Amnion derived adherent cells

Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.

Enhancement of placental stem cell potency using modulatory RNA molecules

Growing community of inventors

Warren, NJ, United States of America

Stewart Abbot